Physician profile
Salim Rizk
NPI 1407989601
$1,336.61
in general payments reported to CMS, 2019-2025
21 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $117 · 2021: $12.36 · 2022: $142 · 2024: $85.36 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.57 | 2019-2024 | Ofev |
| Glaxosmithkline, LLC. | $209.22 | 2019-2021 | |
| Atricure, INC. | $181.14 | 2024-2025 | Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System |
| Idorsia Pharmaceuticals US INC | $73.29 | 2022 | |
| Sunovion Pharmaceuticals INC. | $61.51 | 2019 | |
| Jazz Pharmaceuticals INC. | $56.90 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $56.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $51.10 | 2019-2020 | |
| Resmed Corp | $48.94 | 2019-2020 | |
| Genentech USA, INC. | $41.36 | 2019 | |
| Mylan Specialty L.P. | $32.18 | 2022 | |
| Allergan, INC. | $31.31 | 2019 | |
| Grifols USA, LLC | $30.08 | 2019-2020 | |
| United Therapeutics Corporation | $22.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.76 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $17.30 | 2019 | |
| Shire North American Group INC | $16.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.47 | 2019 | |
| Merck Sharp & Dohme LLC | $14.17 | 2024 | Recarbrio, Dificid, Zerbaxa |
| Biomerieux INC | $12.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salim Rizk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.